Stock Track | STAAR Surgical Soars 15.65% in Pre-Market on Strong Q1 Earnings Beat, China Recovery and Analyst Upgrades

Stock Track05-14

STAAR Surgical Company's stock surged 15.65% during pre-market trading on Thursday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.

The intraocular lens maker reported a swing to profitability with Q1 earnings of $0.10 per diluted share, beating consensus estimates that anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.

Following the earnings release, multiple analysts raised their price targets on the stock. Piper Sandler increased its target to $33 from $16, while Canaccord Genuity raised its target to $32 from $27, reflecting increased confidence in the company's growth trajectory and its plan to supply the Chinese market from its Swiss facility to avoid import tariffs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168119065?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 16:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168119065","market":"nz","top_or_hot":-1,"title":"Stock Track | STAAR Surgical Soars 15.65% in Pre-Market on Strong Q1 Earnings Beat, China Recovery and Analyst Upgrades","media":"Stock Track","content":"<p>STAAR Surgical Company's stock surged 15.65% during pre-market trading on Thursday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.</p><p>The intraocular lens maker reported a swing to profitability with Q1 earnings of $0.10 per diluted share, beating consensus estimates that anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.</p><p>Following the earnings release, multiple analysts raised their price targets on the stock. Piper Sandler increased its target to $33 from $16, while Canaccord Genuity raised its target to $32 from $27, reflecting increased confidence in the company's growth trajectory and its plan to supply the Chinese market from its Swiss facility to avoid import tariffs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | STAAR Surgical Soars 15.65% in Pre-Market on Strong Q1 Earnings Beat, China Recovery and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | STAAR Surgical Soars 15.65% in Pre-Market on Strong Q1 Earnings Beat, China Recovery and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-14 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>STAAR Surgical Company's stock surged 15.65% during pre-market trading on Thursday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.</p><p>The intraocular lens maker reported a swing to profitability with Q1 earnings of $0.10 per diluted share, beating consensus estimates that anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.</p><p>Following the earnings release, multiple analysts raised their price targets on the stock. Piper Sandler increased its target to $33 from $16, while Canaccord Genuity raised its target to $32 from $27, reflecting increased confidence in the company's growth trajectory and its plan to supply the Chinese market from its Swiss facility to avoid import tariffs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STAA","symbol_name":"STAAR Surgical Company","start_time":0,"source_url":"","article_id":"1168119065","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168119065","pubTimestamp":1778746108,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"STAAR Surgical Company's stock surged 15.65% during pre-market trading on Thursday, following the release of its first-quarter 2026 financial results that significantly exceeded market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STAA":"STAAR Surgical Company"},"translate_title":"个股追踪|STAAR Surgical盘前飙升15.65%，因Q1盈利强劲、中国复苏和分析师上调评级","themeId":"a864cd6c65a287045b3e5b828572bce6","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAA":1},"content_text":"STAAR Surgical Company's stock surged 15.65% during pre-market trading on Thursday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.The intraocular lens maker reported a swing to profitability with Q1 earnings of $0.10 per diluted share, beating consensus estimates that anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.Following the earnings release, multiple analysts raised their price targets on the stock. Piper Sandler increased its target to $33 from $16, while Canaccord Genuity raised its target to $32 from $27, reflecting increased confidence in the company's growth trajectory and its plan to supply the Chinese market from its Swiss facility to avoid import tariffs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168119065","isCrawlerRequest":true}